Aoxing Pharmaceutical Company Inc (AOXG) financial statements (2020 and earlier)
Company profile
| Business Address |
1098 FOSTER CITY BLVD. FOSTER CITY, CA 94404 |
| State of Incorp. | FL |
| Fiscal Year End | June 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 6/30/2016 | 6/30/2015 | 6/30/2014 | 6/30/2013 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 7 | 5 | 2 | 4 | ||
| Cash and cash equivalents | 7 | 5 | 2 | 4 | ||
| Receivables | 11 | 6 | 4 | 3 | ||
| Inventory, net of allowances, customer advances and progress billings | 3 | 3 | 2 | 3 | ||
| Inventory | 3 | 3 | 2 | 3 | ||
| Intangible current assets | 2 | 0 | ✕ | ✕ | ||
| Other undisclosed current assets | 4 | 6 | 3 | 2 | ||
| Total current assets: | 27 | 21 | 11 | 12 | ||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 26 | 29 | 26 | 27 | ||
| Long-term investments and receivables | 0 | 0 | 0 | 0 | ||
| Long-term investments | 0 | 0 | 0 | 0 | ||
| Intangible assets, net (including goodwill) | 2 | 0 | 1 | ✕ | ||
| Intangible assets, net (excluding goodwill) | 2 | 0 | 1 | |||
| Other undisclosed noncurrent assets | 2 | 3 | 1 | |||
| Total noncurrent assets: | 29 | 32 | 27 | 28 | ||
| TOTAL ASSETS: | 56 | 53 | 38 | 40 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 10 | 7 | 4 | 4 | ||
| Accounts payable | 3 | 4 | 4 | 3 | ||
| Accrued liabilities | 0 | 1 | 0 | |||
| Employee-related liabilities | 1 | 2 | 1 | |||
| Taxes payable | 3 | 1 | 0 | 0 | ||
| Interest and dividends payable | 3 | 2 | 1 | |||
| Other undisclosed accounts payable and accrued liabilities | 0 | (3) | (2) | 1 | ||
| Debt | 25 | 29 | 22 | 12 | ||
| Due to related parties | 0 | 0 | 1 | 2 | ||
| Customer advances and deposits | 0 | 0 | 1 | ✕ | ||
| Other undisclosed current liabilities | 2 | 5 | 6 | 3 | ||
| Total current liabilities: | 38 | 41 | 34 | 22 | ||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 1 | 1 | 12 | |||
| Long-term debt, excluding current maturities | 1 | 1 | 12 | |||
| Liabilities, other than long-term debt | 0 | 6 | 2 | |||
| Due to related parties | 0 | 6 | 2 | |||
| Other undisclosed noncurrent liabilities | 0 | 0 | 0 | 0 | ||
| Total noncurrent liabilities: | 0 | 2 | 8 | 13 | ||
| Total liabilities: | 38 | 43 | 42 | 35 | ||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent | 19 | 11 | (3) | 6 | ||
| Common stock | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 74 | 66 | 58 | 58 | ||
| Accumulated other comprehensive income | 2 | 3 | 3 | 3 | ||
| Accumulated deficit | (56) | (58) | (64) | (56) | ||
| Stockholders' equity attributable to noncontrolling interest | (1) | (1) | (2) | (1) | ||
| Total stockholders' equity: | 18 | 10 | (4) | 5 | ||
| TOTAL LIABILITIES AND EQUITY: | 56 | 53 | 38 | 40 | ||
Income statement (P&L) ($ in millions)
| 6/30/2016 | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|
| Revenues (Revenue, Net) | 32 | 25 | 13 | 11 | |
| Cost of revenue (Cost of Goods and Services Sold) | (8) | (6) | (7) | (5) | |
| Gross profit: | 25 | 20 | 6 | 6 | |
| Operating expenses | (18) | (11) | (9) | (20) | |
| Other operating income (expense), net (Other Expenses) | 3 | 6 | 5 | (3) | |
| Other undisclosed operating income (loss) | (3) | (6) | (5) | 3 | |
| Operating income (loss): | 6 | 9 | (3) | (14) | |
| Income (loss) from continuing operations before equity method investments, income taxes: | 6 | 9 | (3) | (14) | |
| Loss from equity method investments | (0) | (0) | (0) | (0) | |
| Other undisclosed loss from continuing operations before income taxes | (3) | (5) | (5) | (3) | |
| Income (loss) from continuing operations before income taxes: | 3 | 3 | (9) | (17) | |
| Income tax expense (benefit) | (1) | 3 | (2) | ||
| Income (loss) before gain (loss) on sale of properties: | 2 | 6 | (11) | (17) | |
| Other undisclosed net income (loss) | (0) | 3 | |||
| Net income (loss): | 2 | 5 | (8) | (17) | |
| Net income (loss) attributable to noncontrolling interest | (0) | (0) | 0 | 0 | |
| Other undisclosed net income (loss) attributable to parent | 1 | (1) | |||
| Net income (loss) available to common stockholders, diluted: | 2 | 6 | (9) | (17) | |
Comprehensive Income ($ in millions)
| 6/30/2016 | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|
| Net income (loss): | 2 | 5 | (8) | (17) | |
| Other comprehensive income (loss) | 1 | (0) | (0) | ||
| Other undisclosed comprehensive income (loss) | (3) | 0 | 0 | 1 | |
| Comprehensive income (loss): | 1 | 6 | (8) | (16) | |
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (0) | (0) | 0 | (0) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 0 | 0 | (0) | 0 | |
| Comprehensive income (loss), net of tax, attributable to parent: | 1 | 6 | (8) | (17) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.